Related Experiment Video

Updated: Oct 24, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Toward personalized treatment approaches for non-small-cell lung cancer

Meina Wang1, Roy S Herbst2, Chris Boshoff3,4

  • 1Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.

Nature Medicine
|August 13, 2021
PubMed

Insights

Lung cancer remains a leading cause of cancer deaths globally. New targeted and immune therapies offer hope for non-small-cell lung cancer (NSCLC), but resistance remains a challenge.

Area of Science:

  • Oncology
  • Cancer Research
  • Pulmonology

Background:

  • Lung cancer is the leading cause of cancer mortality worldwide.
  • Recent advances in targeted therapies and immunotherapies have improved outcomes for non-small-cell lung cancer (NSCLC).
  • Treatment resistance is a major obstacle in managing advanced NSCLC.

Purpose of the Study:

  • To review recent breakthrough therapies for NSCLC, including immunotherapies and targeted therapies.
  • To discuss current understanding of resistance mechanisms in NSCLC.
  • To explore future directions in NSCLC treatment, including combination therapies and biomarker development.

Main Methods:

  • Review of recent literature on NSCLC therapies, resistance mechanisms, and clinical research.
  • Focus on immunotherapies and targeted therapies.
  • Discussion of genomic analyses and predictive biomarkers for patient stratification.

Main Results:

  • Significant progress has been made in NSCLC treatment with targeted and immune therapies.
  • Mechanisms of resistance to these therapies are being elucidated.
  • Genomic analyses are crucial for understanding and overcoming resistance.
  • Neoadjuvant and maintenance combination therapies show promise for early-stage disease.

Conclusions:

  • Overcoming treatment resistance is critical for improving NSCLC patient outcomes.
  • Genomic insights and robust biomarkers are essential for developing effective combination therapies.
  • Future NSCLC management will likely involve personalized treatment strategies based on molecular profiling and advanced therapeutic combinations.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.7K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
777
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.7K